|
|
| General |
| Study Status |
Protocol Pending |
Application Number / Requirement Number |
P250021 / PAS002 |
| Date Original Protocol Accepted |
10/07/2026
|
| Date Current Protocol Accepted |
10/07/2026
|
| Study Name |
PAS/Scale Validation
|
| Device Name |
saypha® ChiQ™
|
| General Study Protocol Parameters |
| Study Design |
Other Study Design
|
| Data Source |
New Data Collection
|
| Comparison Group |
Objective Performance Criterion
|
| Analysis Type |
Descriptive
|
| Study Population |
Adult: At least 22 yrs
|
| Detailed Study Protocol Parameters |
| Study Objectives |
The objective of this study is to determine the inter-rater and intra-rater reliability of the Croma Midface Volume Deficit Severity Scale when utilized in live subjects and to confirm that a 1-point difference on the scale is clinically relevant across all FST.
|
| Study Population |
Age 18 years or older
|
| Sample Size |
Approximately fifty (50) subjects will participate in the image capture for the supplemental study. Live Validation (LV): Of these, approximately thirty-three (33) subjects will participate in the Live Validation, and approximately ten (10) subjects will participate in live rater training. Clinical Relevance (CR): 30 image pairs will be selected; target ten 0-point difference, ten 1-point difference, five 2-point difference, three 3-point difference, and two 4-point difference; target 5 FST I, 15 FST V, 10 FST VI.
|
| Key Study Endpoints |
Live Validation (LV) Intra-rater: Overall Fleiss-Cohen weighted kappa coefficient of the three (3) Live Validation (LV) Raters based on MVDSS scores assigned by LV raters during LV Rounds 1 and 2. Data will be presented independently from this study, and if appropriate pooled across the original and supplemental studies. Inter-rater: Median pairwise Fleiss-Cohen weighted kappa coefficients for each pairwise combination of the three (3) LV Raters based on MVDSS scores assigned by LV Raters during LV Round 1. Data will be presented independently from this study, and if appropriate pooled across the original and supplemental studies. Clinical Relevance (CR) • Difference (and corresponding 95% CI) in estimated marginal means of MVDSS scores assigned by CR Reviewers, for image pairs with 0-point True Grade difference versus pairs with 1-point True Grade difference, modeling rater and image pair as random effects. Secondary Endpoints For all secondary endpoints data will be presented independently from this study, and if appropriate pooled across the original and supplemental studies. Intra-rater: • Point estimate of Fleiss-Cohen weighted kappa coefficient for each of the three (3) LV Raters, based on MVDSS scores assigned by LV Raters during LV Rounds 1 and 2. • Point estimate of intra-rater ICC for each of the three (3) LV Raters, based on MVDSS scores assigned by LV Raters during LV Rounds 1 and 2. • Percent agreement of MVDSS ratings between LV Rounds 1 and 2 for each of the three (3) LV Raters. • Overall Cicchetti-Allison weighted kappa coefficients of the three (3) Live Validation (LV) Raters based on MVDSS scores assigned by LV raters during LV Rounds 1 and 2. Data will be presented independently from this study, and if appropriate pooled across the original and supplemental studies. Inter-rater: • Point estimate of Fleiss-Cohen kappa coefficient for each pairwise combination of the three (3) LV Raters calculated separately for MVDSS scores assigned by LV Raters during LV Round 1 and 2. • Point estimate of ICC for each pairwise combination of the three (3) LV Raters calculated separately for MVDSS scores assigned by LV Raters during LV Round 1 and 2. • Percent agreement of MVDSS ratings for each pairwise combination of the three (3) LV Raters during LV Rounds 1 and 2. • Percent agreement, point estimate of intraclass correlation coefficient (ICC) and Fleiss-Cohen kappa coefficient for each of the three (3) LV Raters calculated against the median 3-rater score, separately LV Round 1 and 2. • Median pairwise Cicchetti-Allison weighted kappa coefficients for each pairwise combination of the three (3) LV Raters based on MVDSS scores assigned by LV Raters during LV Round 1. Data will be presented independently from this study and if appropriate pooled across the original and supplemental studies.
|
| Follow-up Visits and Length of Follow-up |
Study duration is minimum of two (2) weeks (for participation in the live validation rounds). The two (2) rounds of Clinical Relevance can be completed together or separately; however, the comparison review must be completed first.
|
| General |
| Study Status |
Study Pending |
Application Number / Requirement Number |
P250021 / PAS001 |
| Date Original Protocol Accepted |
10/08/2026
|
| Date Current Protocol Accepted |
10/08/2026
|
| Study Name |
VOLIDO-PAS (PAS/FST)
|
| Device Name |
saypha® ChiQ™
|
| General Study Protocol Parameters |
| Study Design |
Other Study Design
|
| Data Source |
New Data Collection
|
| Comparison Group |
No Control
|
| Analysis Type |
Descriptive
|
| Study Population |
Adult: At least 22 yrs
|
| Detailed Study Protocol Parameters |
| Study Objectives |
The primary objective of this study is to characterize the safety profile of subjects with Fitzpatrick skin types V and VI treated with saypha® ChIQ™ for moderate to severe midface volume deficit. Therefore, the sample size was selected to provide a reliable estimate for the incidence of selected AEs in subjects with Fitzpatrick skin types V and VI.
|
| Study Population |
Single-arm post-approval safety study in subjects with Fitzpatrick skin types V and VI treated with saypha® ChIQ™ for moderate to severe midface volume deficit to further characterize the safety profile in this subpopulation.
|
| Sample Size |
Number of subjects: Approximately 50 subjects will need to be screened [enrolled] to reach 45 subjects treated and included in the Safety Analysis Set (SAF), assuming a screening failure rate of approx. 10% and a follow-up completion rate of greater than or equal to 85%. Sites will employ reminder calls and flexible scheduling to minimize losses to follow-up. Number of sites: approximately 4-5 investigation sites in U.S. with enrolment target of approximately 10 to 13 subjects per site Sites location: U.S.
|
| Key Study Endpoints |
Safety Endpoints Primary: Incidence, severity, seriousness, relatedness, and outcome of treatment-emergent device- and/or procedure related adverse events through Week 24 after last injection Secondary: Injection site reactions as recorded in the subject diaries during the first 4 weeks (28 days) after each treatment (i.e., either 4 weeks total after baseline or 6 weeks total in case of touch-up treatment). Injection site reactions will be assessed overall and for each side of the midface (i.e., left and right side separately) Subject evaluation of pain after each treatment on an 11-point NPRS (0 = no pain; 10 = worst pain imaginable) Effectiveness Endpoints Responder a status on the 5-point MVDSS based on evaluating investigator's live assessment at Weeks 4, 8, 16, and 24 after last injection compared to baseline Responder a status on the 5-point MVDSS, based on the independent photographic reviewers’ assessment by using baseline photographs at Week 4, 8, 16 and 24 after last injection compared to the score at baseline a Note: Subjects are defined as responders if they demonstrate an improvement of greater than or equal to 1 point on the 5 point MVDSS relative to baseline. The grade assigned at the baseline visit will serve as the baseline value for derivation of responder status at each post-baseline visit. Assessments will be performed by the evaluating investigator, and by the independent photographic reviewers in the corresponding assessments. Change in midface volume deficit measured on the 5 point MVDSS based on evaluating investigator's live assessment at Weeks 4, 8, 16, and 24 after last injection compared to baseline Global aesthetic improvement (subjects rated as "much improved" or "improved") based on subject's and evaluating investigator's assessment using the 5-point modified GAIS at Weeks 4, 8, 16, and 24 Subject's satisfaction with outcome and appearance appraisal based on FACE-Q™ "Satisfaction with Outcome" questionnaire at Weeks 4, 8, 16, and 24 after last injection and "Satisfaction with Cheeks" questionnaire at Weeks 4, 8, 16, and 24 after last injection compared to baseline Injection volume required to achieve optimal aesthetic result at each treatment session Shift from baseline in nasolabial folds measured by NLF-SRS based on the evaluating investigator´s live assessment at Week 4, 8, 16 and 24 after the last injection compared to baseline
|
| Follow-up Visits and Length of Follow-up |
Each subject will participate in the investigation for up to 28 weeks (up to 2 weeks screening period + baseline treatment + optional touch-up treatment at Week 2 + 24 weeks follow-up)
|